Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.

Siders WM, Shields J, Kaplan J, Lukason M, Woodworth L, Wadsworth S, Scaria A.

Hum Gene Ther. 2009 Jan;20(1):11-20. doi: 10.1089/hum.2008.055.

2.

The complex and evolving story of T cell activation to AAV vector-encoded transgene products.

Mays LE, Wilson JM.

Mol Ther. 2011 Jan;19(1):16-27. doi: 10.1038/mt.2010.250. Epub 2010 Nov 30. Review.

3.

Immune responses to AAV in clinical trials.

Mingozzi F, High KA.

Curr Gene Ther. 2011 Aug;11(4):321-30. Review.

PMID:
21557723
4.

AAV as an immunogen.

Vandenberghe LH, Wilson JM.

Curr Gene Ther. 2007 Oct;7(5):325-33. Review.

PMID:
17979679
5.

Immune responses to AAV in clinical trials.

Mingozzi F, High KA.

Curr Gene Ther. 2007 Oct;7(5):316-24. Review.

PMID:
17979678
6.

Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.

Chamberlain K, Riyad JM, Weber T.

Hum Gene Ther Methods. 2016 Feb;27(1):1-12. doi: 10.1089/hgtb.2015.140. Review.

7.

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T.

Hum Gene Ther Methods. 2013 Apr;24(2):59-67. doi: 10.1089/hgtb.2012.243. Epub 2013 Apr 3. Review.

8.

Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors.

Basner-Tschakarjan E, Bijjiga E, Martino AT.

Front Immunol. 2014 Feb 7;5:28. doi: 10.3389/fimmu.2014.00028. eCollection 2014. Review.

9.

Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Mingozzi F, High KA.

Blood. 2013 Jul 4;122(1):23-36. doi: 10.1182/blood-2013-01-306647. Epub 2013 Apr 17. Review.

10.

Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity.

McCown TJ.

Neurotherapeutics. 2009 Apr;6(2):307-11. doi: 10.1016/j.nurt.2009.01.004. Review.

11.

Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering.

Sen D.

J Biomed Sci. 2014 Nov 26;21:103. doi: 10.1186/s12929-014-0103-1. Review.

12.

Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Matthews QL.

Mol Pharm. 2011 Feb 7;8(1):3-11. doi: 10.1021/mp100214b. Epub 2010 Dec 1. Review.

13.

Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy.

Powell SK, Rivera-Soto R, Gray SJ.

Discov Med. 2015 Jan;19(102):49-57. Review.

14.

Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.

Basner-Tschakarjan E, Mingozzi F.

Front Immunol. 2014 Jul 23;5:350. doi: 10.3389/fimmu.2014.00350. eCollection 2014. Review.

15.

AAV Vectors Vaccines Against Infectious Diseases.

Nieto K, Salvetti A.

Front Immunol. 2014 Jan 21;5:5. doi: 10.3389/fimmu.2014.00005. eCollection 2014. Review.

16.

Immunological Monitoring to Rationally Guide AAV Gene Therapy.

Britten CM, Walter S, Janetzki S.

Front Immunol. 2013 Sep 12;4:273. doi: 10.3389/fimmu.2013.00273. Review.

Supplemental Content

Support Center